• LAST PRICE
    21.5600
  • TODAY'S CHANGE (%)
    Trending Up0.2900 (1.3634%)
  • Bid / Lots
    21.5200/ 3
  • Ask / Lots
    21.5800/ 2
  • Open / Previous Close
    21.2300 / 21.2700
  • Day Range
    Low 21.1600
    High 21.7350
  • 52 Week Range
    Low 12.3202
    High 32.1000
  • Volume
    154,475
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 21.27
TimeVolumeSAVA
09:32 ET733421.16
09:34 ET138421.3879
09:36 ET406121.4883
09:38 ET34021.405
09:39 ET169121.43
09:41 ET160021.3806
09:43 ET361021.35
09:45 ET272021.29
09:48 ET481421.3399
09:50 ET363221.36
09:52 ET241321.49
09:54 ET122521.4501
09:56 ET280221.405
09:59 ET129821.37
10:01 ET86421.38
10:03 ET102421.38
10:06 ET408321.29
10:08 ET211721.3807
10:10 ET95021.3885
10:12 ET10021.39
10:14 ET220621.478
10:15 ET354721.43
10:17 ET1220421.48
10:19 ET381721.53
10:21 ET40021.495
10:24 ET747721.6292
10:26 ET931821.54
10:28 ET504721.675
10:30 ET230021.65
10:32 ET3158621.65
10:33 ET40021.56
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSAVA
Cassava Sciences Inc
919.8M
-9.3x
---
United StatesZNTL
Zentalis Pharmaceuticals Inc
901.9M
-2.8x
---
United StatesVRDN
Viridian Therapeutics Inc
946.5M
-2.8x
---
United StatesKYTX
Kyverna Therapeutics Inc
880.8M
-14.3x
---
United StatesBLTE
Belite Bio Inc
962.0M
-26.2x
---
United StatesSPRY
ARS Pharmaceuticals Inc
874.3M
-15.4x
---
As of 2024-04-18

Company Information

Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

Contact Information

Headquarters
6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX, United States 78731
Phone
512-501-2444
Fax
512-614-0414

Executives

Chairman of the Board, President, Chief Executive Officer
Remi Barbier
Chief Financial Officer
Eric Schoen
Senior Vice President, General Counsel
R. Christopher Cook
Chief Medical Officer
James Kupiec
Lead Independent Director
Sanford Robertson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$919.8M
Revenue (TTM)
$0.00
Shares Outstanding
43.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.36
EPS
$-2.32
Book Value
$3.25
P/E Ratio
-9.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.